Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-06-057838
Filing Date
2006-11-06
Accepted
2006-11-06 14:20:51
Documents
1
Period of Report
2006-11-02

Document Format Files

Seq Description Document Type Size
1 MAIN DOCUMENT DESCRIPTION bsf24903_bsf2ag.html 4  
1 MAIN DOCUMENT DESCRIPTION bsf24903_bsf2ag.xml 4 5788
  Complete submission text file 0001209191-06-057838.txt   7747
Mailing Address THE JOHN HANCOCK TOWER 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116
Business Address ONE CAMBRIDGE CENTER CAMBRIDGE MA 02142 6174259200
GADICKE ANSBERT (Reporting) CIK: 0001134655 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-51905 | Film No.: 061189764

Mailing Address 630 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10111
Business Address 630 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10111 (212) 887-6500
Omrix Biopharmaceuticals, Inc. (Issuer) CIK: 0001349426 (see all company filings)

EIN.: 522147005 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)